Perception and safety analysis of COVID-19 vaccination in cancer patients: A multicenter, real-world study

Kyoungmin Lee, In Hae Park, Sang Cheul Oh, Jae Hong Seo, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Chul Won Choi, Ah reum Lim, Myung Han Hyun, Ju Won Kim, Jwa Hoon Kim, Yoon Ji Choi, Soohyeon Lee, Kyong Hwa Park, Yeul Hong Kim, Jung Yoon Choi, Jung Sun Kim, Se Ryeon Lee, Hwa Jung SungEun Joo Kang

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background: Although various coronavirus disease 2019 (COVID-19) vaccines have been delivered to the public worldwide, data on cancer populations are limited. Vaccine hesitancy related to safety concerns is observed among cancer patients. We report the perception of COVID-19 vaccines and their safety profile after vaccination among cancer patients. Materials and Methods: Between April and November 2021, a multicenter survey was conducted on 318 patients treated in any hemato-oncology outpatient clinic among three hospitals under the Korea University Medical Center. The medical records of the patients were reviewed to obtain detailed clinical and hematological toxicity data. Results: A perception survey was conducted among 293 patients. Among them, 53.9% were concerned about developing vaccine-related adverse events (VRAEs) and 23.5%, about negative effects on cancer treatment. During the study period, 255 and 186 patients participated in a safety survey after the first and second doses, respectively. After the first dose, 62% of patients reported VRAEs (2.4%, grade 3), whereas 48.9% reported VRAEs (2.7%, grade 3) after the second dose. For both doses, injection-site pain and sore arm pain were the most common VRAEs, followed by myalgia, fatigue, and headache. No grade 4/5 VRAEs were observed, and there were no differences in complete blood count after vaccination. Multivariate analysis revealed female sex, active cancer treatment, and mRNA vaccines as independent risk factors for VRAE development in cancer patients. Conclusion: Despite high levels of concern, COVID-19 vaccines were well tolerated by cancer patients, with a safety profile consistent with that of the general population.

Original languageEnglish
Pages (from-to)5558-5568
Number of pages11
JournalCancer medicine
Issue number5
Publication statusPublished - 2023 Mar

Bibliographical note

Publisher Copyright:
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.


  • cancer patients
  • coronavirus disease 2019
  • perception
  • safety
  • vaccine

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Perception and safety analysis of COVID-19 vaccination in cancer patients: A multicenter, real-world study'. Together they form a unique fingerprint.

Cite this